^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The Clinical Effect of EGFR-TKI Combined with Chemotherapy on Patients with EGFR Multiple Mutation

    Excerpt:
    ...EGFR sensitive mutation positive, and EGFR T790M negative; 9. ...
    Trial ID:
    ChiCTR1800016672
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Treat Res Commun
    Title:

    Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)

    Excerpt:
    For patients with advanced lung adenocarcinoma harboring sensitive EGFR mutations, after failed first-line EGFR-TKI, the efficacy of pemetrexed-based therapy was superior to other chemotherapy agents in PFS and survival after failure of first-line EGFR-TKI.
    DOI:
    https://doi.org/10.1016/j.ctarc.2016.07.005